Moreover, treatment with an anti-CD200 antibody can specifically facilitate the phagocytosis of CD200+ AML cells by macrophages through a process called antibody-dependent cell phagocytosis (ADCP) [286]. Here, CD200 is linked to acute myeloid leukemia.